Our overarching goal is to develop biomarkers that are useful in informing clinical management of CT detected lung nodules of indeterminate etiology. Biomarkers assayed in non-invasively obtained biospecimens need to be developed to enhance the performance of currently evolving lung cancer risk models which are based solely on demographics, clinical and imaging characteristics. We hypothesize: 1. Biomarkers measurable in non-invasively obtained specimens can discriminate between benign and malignant lung nodules detected by CT. 2. These biomarkers can be incorporated into a prediction model to aid clinical decision making and potentially improve outcomes by shortening time to diagnosis of lung cancer, decreasing biopsy and/or surgery for benign disease, reducing patient anxiety and decreasing costs. In the current SPORE grant period, we have developed several promising biomarkers and carried out initial validation steps. We now are in the position to assess these prospectively and simultaneously in a population in which they would have immediate clinical applicability, through the following Specific Aims: 1. Develop and test novel measurement tools for the following biomarkers in non-invasively obtained specimens, including: a) Epithelial chromosomal imbalances;b) Circulating protein levels;c) Exhaled breath volatile organic compounds;d) miRNA expression patterns. 2. Compare the performance of the individual biomarkers singly and in combinations in discriminating benign from malignant nodules in a cohort of subjects with indeterminate lung nodules referred to specialty clinics for evaluation. 3. Develop a model based on biomarker outcomes, smoking history, clinical and imaging features for the prediction of malignancy in CT detected lung nodules. We envision that at the end of this project, the above predictive model can be subjected to further prospective validation in independent cohorts of patients with indeterminate CT detected lung nodules, in which changes in specific outcomes (time to diagnosis, invasive procedures for benign disease, costs) can be simulated.

Public Health Relevance

Low dose CT screening for lung cancer has now been demonstrated to result in a reduction in both overall and lung cancer specific mortality, but with a high false positive rate which leads to patient anxiety, unnecessary invasive procedures, delays in diagnosis and costs. Biomarkers have the potential to improve the clinical management of CT detected lung nodules. This project will evaluate 4 promising biomarkers prospectively and simultaneously in the setting of indeterminate lung nodules;we will incorporate results into a predictive model to aid in clinical management.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Vaishnavi, Aria; Le, Anh T; Doebele, Robert C (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25-34
Toschi, Luca; Finocchiaro, Giovanna; Nguyen, Teresa T et al. (2014) Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. PLoS One 9:e95303
Marek, Lindsay A; Hinz, Trista K; von Mässenhausen, Anne et al. (2014) Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res 12:1460-9
Brosnan, Evelyn M; Weickhardt, Andrew J; Lu, Xian et al. (2014) Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 120:664-74
Wynes, Murry W; Hinz, Trista K; Gao, Dexiang et al. (2014) FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 20:3299-309
Bunn Jr, Paul A; Hirsch, Fred R; Aisner, Dara L (2014) Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res 20:1727-9
Kim, Jihye; Vasu, Vihas T; Mishra, Rangnath et al. (2014) Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics 30:2393-8
Le, Anh T; Doebele, Robert C (2014) The democratization of the oncogene. Cancer Discov 4:870-2
Nakachi, Ichiro; Rice, Jessica L; Coldren, Christopher D et al. (2014) Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila) 7:255-65
Shaw, Alice T; Ou, Sai-Hong I; Bang, Yung-Jue et al. (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-71

Showing the most recent 10 out of 256 publications